Advertisement

Topics

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers

02:32 EDT 23 Jun 2017 | Hoffmann-La Roche Ltd

Roche today announced new data from multiple studies of Venclexta®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid.

Original Article: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers

NEXT ARTICLE

More From BioPortfolio on "Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers"

Advertisement
Quick Search
Advertisement
Advertisement